PLANEGG/MUNICH, GERMANY / ACCESSWIRE / December 12, 2019 / MorphoSys (NASDAQ:MOR) (FSE:MOR):
Dear Madam/Sir,
Please note MorphoSys's financial reporting dates 2020 as follows:
For a direct import of the dates to your calendar, please visit our corporate website: https://www.morphosys.com/media-and-investors/morphosys-events#company-calendar
With season's greetings and good wishes for the New Year:
www.morphosys.com/xmas-2019
About MorphoSys
MorphoSys (FSE & NASDAQ: MOR) is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of exceptional, innovative therapies for patients suffering from serious diseases. The focus is on cancer. Based on its leading expertise in antibody, protein and peptide technologies, MorphoSys, together with its partners, has developed and contributed to the development of more than 100 product candidates, of which 28 are currently in clinical development. In 2017, Tremfya(R), marketed by Janssen for the treatment of plaque psoriasis, became the first drug based on MorphoSys's antibody technology to receive regulatory approval. The Company's most advanced proprietary product candidate, tafasitamab (MOR208), has been granted U.S. FDA breakthrough therapy designation for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Headquartered near Munich, Germany, the MorphoSys group, including the fully owned U.S. subsidiary MorphoSys US Inc., has approximately 405 employees. More information at https://www.morphosys.com.
HuCAL(R), HuCAL GOLD(R), HuCAL PLATINUM(R), CysDisplay(R), RapMAT(R), arYla(R), Ylanthia(R), 100 billion high potentials(R), Slonomics(R), Lanthio Pharma(R), LanthioPep(R) and ENFORCERTM are trademarks of the MorphoSys Group. Tremfya(R) is a trademark of Janssen Biotech, Inc.
| Publication of Interim Statement / Report | Conference Call | |
| Year-End Results 2019 | March 18, 2020 // 10 pm CET (5 pm EDT; 9 pm GMT) |
March 19, 2019 // 2 pm CET (9 am EDT; 1 pm GMT) |
| First Quarter Interim Statement 2020 | May 6, 2020 // 10 pm CEST (4 pm EDT; 9 pm BST) |
May 7, 2020 // 2 pm CEST (8 am EDT; 1 pm BST) |
| Half-Year Report 2020 | Aug. 5, 2020 // 10 pm CEST (4 pm EDT; 9 pm BST) |
Aug. 6, 2020 // 2 pm CEST (8 am EDT; 1 pm BST) |
| Third Quarter Interim Statement 2020 | Nov. 11, 2020 // 10 pm CET (4 pm EST; 9 pm GMT) |
Nov. 12, 2020 // 2 pm CET (8 am EST; 1 pm GMT) |
| Annual General Meeting | May 27, 2020 |
For more information, please contact:
MorphoSys AG
Dr. Sarah Fakih
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-26663
[email protected]
Dr. Julia Neugebauer
Director Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-179
[email protected]
Dr. Verena Kupas
Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-26814
[email protected]
SOURCE: MorphoSys